Summary

KEY FINDINGS
The Europe retinal imaging devices market size is valued at $1,226.22 million as of 2026 and is expected to reach $2,202.75 million by 2034, progressing with a CAGR of 7.60% during the forecast years, 2026-2034.

MARKET INSIGHTS
Europe maintains a strong position in the global retinal imaging devices market, supported by well-established healthcare systems, universal health coverage frameworks, and comprehensive diabetic eye screening programs. The region benefits from advanced medical infrastructure, high physician awareness regarding diabetic retinopathy management, and favorable reimbursement policies for ophthalmic diagnostic procedures.
Moreover, European countries demonstrate strong commitment to preventive healthcare, with national screening initiatives systematically identifying sight-threatening conditions. According to research published in the European Journal of Epidemiology, diabetic retinopathy prevalence in Europe reaches 25.7% among individuals with diabetes, while diabetic macular edema affects 3.7% of this population. Additionally, the region experiences significant demand for advanced retinal diagnostic imaging equipment as aging populations face increased risks of age-related macular degeneration and glaucoma.
European manufacturers like Carl Zeiss Meditec and Heidelberg Engineering lead technological innovation in optical coherence tomography systems and fundus cameras, contributing substantially to the regional market expansion. Furthermore, stringent CE marking requirements ensure high quality standards for retinal imaging equipment distributed throughout European healthcare facilities.

REGIONAL ANALYSIS
The Europe retinal imaging devices market growth assessment includes the analysis of the United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe.
The United Kingdom represents a significant market for retinal imaging devices, driven by its world-leading National Health Service Diabetic Eye Screening Programme. This comprehensive national initiative systematically screens diabetic patients using digital fundus photography, creating substantial demand for retinal imaging cameras and associated diagnostic equipment. According to research in Acta Ophthalmologica, diabetic retinopathy prevalence in Gloucestershire decreased from 38.9% in 2012 to 36.6% in 2016, demonstrating the effectiveness of organized screening efforts.
The NHS screening program offers two-field mydriatic digital photography to all diabetic patients across England, Scotland, Wales, and Northern Ireland, requiring continuous equipment replacement and technology upgrades. Moreover, the UK demonstrates significant ethnic diversity in diabetic retinopathy prevalence, with studies showing rates of 52.4% among African/Afro-Caribbean populations and 42.3% among South Asians compared to 38.0% in white Europeans with type 2 diabetes. This demographic reality necessitates expanded screening capacity and culturally appropriate eye care services.
Furthermore, the UK actively embraces artificial intelligence integration for diabetic retinopathy screening. In November 2024, NHS England began phased integration of advanced OCT scans into post-treatment monitoring pathways, potentially saving tens of thousands of hospital appointments annually. Teleophthalmology programs connect remote grading centers with local screening sites, enabling efficient image analysis by specialized ophthalmologists.
Additionally, the UK's regulatory framework through the Medicines and Healthcare products Regulatory Agency ensures rigorous evaluation of new retinal imaging technologies before clinical deployment. Consequently, vendors offering AI-powered automated grading systems, telehealth-compatible fundus cameras, and ultra-widefield retinal imaging devices find substantial opportunities within the UK market, particularly for serving diverse urban populations and rural communities requiring accessible eye care services.
Germany exhibits robust demand for retinal imaging devices, supported by comprehensive statutory health insurance coverage and high healthcare quality standards. The German healthcare system emphasizes preventive medicine, with diabetic patients receiving regular ophthalmological examinations funded through statutory health insurance schemes.
Research published in Diabetologia found that 13% of screening-detected type 2 diabetes patients in Germany already exhibited diabetic retinopathy at diagnosis, underscoring the importance of systematic retinal screening. Moreover, studies analyzing youth with type 1 diabetes documented that diabetic retinopathy prevalence decreased significantly in Germany during the observational period, reflecting improved diabetes management and screening effectiveness.
German ophthalmology practices extensively utilize advanced optical coherence tomography systems for detailed retinal analysis, creating sustained demand for high-resolution imaging equipment. Additionally, the country's robust medical device industry supports local manufacturing and distribution of retinal diagnostic equipment, with companies like Carl Zeiss Meditec maintaining global leadership positions in ophthalmic technology innovation.

SEGMENTATION ANALYSIS
The Europe retinal imaging devices market is segmented into device, application, and indication. The application segment is further categorized into disease diagnosis, treatment monitoring, and research and development.
Disease diagnosis is an important segment in the European retinal imaging devices market due to the critical role these systems play in early detection of sight-threatening conditions. Healthcare providers across Europe rely on fundus cameras and optical coherence tomography equipment to identify diabetic retinopathy, age-related macular degeneration, and glaucoma before significant vision loss occurs.
National screening programs in the United Kingdom, Denmark, and other European countries systematically employ retinal imaging technology to examine diabetic populations, generating millions of diagnostic examinations annually. Moreover, the segment benefits from comprehensive reimbursement coverage under statutory health insurance schemes, removing financial barriers to diagnostic imaging access.
Ophthalmologists utilize these systems during routine examinations to detect subtle retinal changes that precede symptomatic disease progression. Additionally, primary care physicians increasingly adopt portable retinal imaging devices for point-of-care diabetic retinopathy screening, extending diagnostic capabilities beyond traditional ophthalmology settings. The COVID-19 pandemic accelerated adoption of remote diagnostic services, with healthcare systems deploying connected retinal imaging cameras that transmit images to centralized grading centers for specialist evaluation.
Consequently, vendors offering user-friendly, cost-effective diagnostic systems with artificial intelligence-powered automated analysis capabilities capture significant market share. Furthermore, aging European populations face elevated risks of vision-threatening conditions, creating sustained demand for diagnostic retinal imaging equipment throughout hospitals, ophthalmology clinics, optometry practices, and primary care facilities across the region.

COMPETITIVE INSIGHTS
Some of the top players operating in the Europe retinal imaging devices market include Carl Zeiss Meditec AG, Heidelberg Engineering GmbH, Topcon Corporation, Nidek Co Ltd, etc.
Heidelberg Engineering GmbH stands as a premier European manufacturer of ophthalmic diagnostic imaging equipment, headquartered in Heidelberg, Germany. The company specializes in advanced retinal imaging systems, particularly its renowned Spectralis platform combining spectral-domain optical coherence tomography with confocal scanning laser ophthalmoscopy technology.
Heidelberg Engineering's product portfolio encompasses comprehensive diagnostic solutions including OCT-angiography modules, ultra-widefield imaging systems, multimodal imaging platforms, and software solutions for image management and analysis. Additionally, Heidelberg Engineering offers the Anterion platform for anterior segment OCT imaging and the HEYEX image management system that facilitates efficient data handling across multiple devices.
The company serves diverse customer segments throughout Europe including university hospitals, retina specialty centers, comprehensive ophthalmology practices, optometry clinics, and research institutions. Heidelberg Engineering's business model emphasizes premium quality positioning, exceptional technical support services, comprehensive training programs for clinical staff, and long-term customer relationships built on product reliability and diagnostic accuracy.

COMPANY PROFILES
1. CANON INC
2. CARL ZEISS MEDITEC AG
3. ESCALON MEDICAL CORP
4. FORUS HEALTH PVT LTD
5. HEIDELBERG ENGINEERING GMBH
6. KOWA COMPANY LTD
7. NIDEK CO LTD
8. OPTOS PLC
9. SANTEC CORPORATION
10. TOPCON CORPORATION

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & FORECAST
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. WIDESPREAD ADOPTION OF FUNDUS CAMERAS AND OCT SYSTEMS IS DRIVEN BY RISING SCREENING NEEDS FOR DIABETIC RETINOPATHY AND AGE-RELATED MACULAR DEGENERATION
2.5.2. HOSPITALS AND DIAGNOSTIC CLINICS ACCOUNT FOR THE LARGEST SHARE DUE TO HIGH PATIENT FOOTFALL AND INTEGRATED OPHTHALMOLOGY SETUPS
2.5.3. PORTABLE AND HANDHELD RETINAL IMAGING DEVICES ARE GAINING TRACTION IN RURAL AND PRIMARY CARE SETTINGS
2.5.4. DEVELOPED MARKETS DOMINATE REVENUE, WHILE EMERGING ECONOMIES SHOW FASTER VOLUME GROWTH
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING GLOBAL PREVALENCE OF DIABETES AND AGING POPULATION IS EXPANDING THE AT-RISK PATIENT BASE
3.1.2. GOVERNMENT AND NGO LED EYE SCREENING PROGRAMS ARE BOOSTING DEMAND FOR RETINAL DIAGNOSTIC TOOLS
3.1.3. TECHNOLOGICAL ADVANCES IN OCT AI ASSISTED DIAGNOSTICS AND IMAGE QUALITY ARE IMPROVING CLINICAL OUTCOMES
3.1.4. RISING AWARENESS AMONG PHYSICIANS AND PATIENTS ABOUT EARLY DETECTION OF RETINAL DISORDERS IS SUPPORTING MARKET EXPANSION
3.2. KEY RESTRAINTS
3.2.1. HIGH CAPITAL COST OF ADVANCED RETINAL IMAGING SYSTEMS LIMITS ADOPTION IN SMALL CLINICS
3.2.2. LACK OF TRAINED OPHTHALMOLOGISTS AND TECHNICIANS CONSTRAINS EFFECTIVE UTILIZATION IN LOW-INCOME REGIONS
3.2.3. REIMBURSEMENT VARIABILITY ACROSS COUNTRIES AFFECTS PURCHASE DECISIONS BY HEALTHCARE PROVIDERS
3.2.4. REGULATORY APPROVAL AND DEVICE CERTIFICATION REQUIREMENTS CAN DELAY PRODUCT COMMERCIALIZATION
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. INTEGRATION OF ARTIFICIAL INTELLIGENCE FOR AUTOMATED RETINAL IMAGE ANALYSIS IS ACCELERATING
4.1.2. SHIFT TOWARD NON-MYDRIATIC AND PATIENT-FRIENDLY IMAGING SYSTEMS IS IMPROVING SCREENING COMPLIANCE
4.1.3. GROWING USE OF TELE OPHTHALMOLOGY IS DRIVING DEMAND FOR CONNECTED RETINAL IMAGING DEVICES
4.1.4. MANUFACTURERS ARE FOCUSING ON COMPACT AND PORTABLE DESIGNS TO EXPAND POINT OF CARE APPLICATIONS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR EUROPE
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. RAW MATERIAL SUPPLIERS
4.6.2. OPTICAL COMPONENTS
4.6.3. DEVICE MANUFACTURING
4.6.4. SOFTWARE DEVELOPMENT
4.6.5. DISTRIBUTION CHANNELS
4.6.6. HOSPITALS AND CLINICS
4.6.7. AFTERSALES SUPPORT
4.7. KEY BUYING CRITERIA
4.7.1. IMAGE RESOLUTION
4.7.2. CLINICAL ACCURACY
4.7.3. EASE OF USE
4.7.4. TOTAL COST OWNERSHIP
4.8. REGULATORY FRAMEWORK
5. RETINAL IMAGING DEVICES MARKET BY DEVICE
5.1. OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES
5.1.1. SPECTRAL-DOMAIN OCT (SD-OCT)
5.1.2. SWEPT-SOURCE OCT (SS-OCT)
5.1.3. HANDHELD OCT
5.2. FLUORESCEIN ANGIOGRAPHY DEVICES
5.3. FUNDUS CAMERAS
5.3.1. MYDRIATIC FUNDUS CAMERAS
5.3.2. NON-MYDRIATIC FUNDUS CAMERAS
5.3.3. HYBRID FUNDUS CAMERAS
5.3.4. ROP FUNDUS CAMERAS
5.4. RETINAL ULTRASOUND IMAGING SYSTEMS
5.4.1. OPHTHALMIC A-SCAN ULTRASOUND
5.4.2. OPHTHALMIC B-SCAN ULTRASOUND
5.4.3. OPHTHALMIC ULTRASOUND BIOMICROSCOPES
5.4.4. OPHTHALMIC PACHYMETERS
5.5. ULTRA WIDEFIELD RETINAL IMAGING DEVICES
5.6. WIDEFIELD RETINAL IMAGING DEVICES
5.7. OTHER DEVICES
6. RETINAL IMAGING DEVICES MARKET BY APPLICATION
6.1. DISEASE DIAGNOSIS
6.2. TREATMENT MONITORING
6.3. RESEARCH AND DEVELOPMENT
7. RETINAL IMAGING DEVICES MARKET BY INDICATION
7.1. DIABETIC RETINOPATHY
7.2. AGE-RELATED MACULAR DEGENERATION (AMD)
7.3. GLAUCOMA
7.4. RETINAL VEIN OCCLUSION
7.5. OTHER INDICATIONS
8. GEOGRAPHICAL ANALYSIS
8.1. EUROPE
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. EUROPE MARKET DRIVERS
8.1.3. EUROPE RETINAL IMAGING DEVICES MARKET CHALLENGES
8.1.4. KEY PLAYERS IN EUROPE RETINAL IMAGING DEVICES MARKET
8.1.5. COUNTRY ANALYSIS
8.1.5.1. GERMANY
8.1.5.1.1. GERMANY MARKET SIZE & OPPORTUNITIES
8.1.5.2. UNITED KINGDOM
8.1.5.2.1. UNITED KINGDOM MARKET SIZE & OPPORTUNITIES
8.1.5.3. FRANCE
8.1.5.3.1. FRANCE MARKET SIZE & OPPORTUNITIES
8.1.5.4. ITALY
8.1.5.4.1. ITALY MARKET SIZE & OPPORTUNITIES
8.1.5.5. SPAIN
8.1.5.5.1. SPAIN MARKET SIZE & OPPORTUNITIES
8.1.5.6. BELGIUM
8.1.5.6.1. BELGIUM MARKET SIZE & OPPORTUNITIES
8.1.5.7. POLAND
8.1.5.7.1. POLAND MARKET SIZE & OPPORTUNITIES
8.1.5.8. REST OF EUROPE
8.1.5.8.1. REST OF EUROPE MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. CANON INC
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. PRODUCT LIST
9.2.1.3. STRENGTHS & CHALLENGES
9.2.2. CARL ZEISS MEDITEC AG
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. PRODUCT LIST
9.2.2.3. STRENGTHS & CHALLENGES
9.2.3. ESCALON MEDICAL CORP
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. PRODUCT LIST
9.2.3.3. STRENGTHS & CHALLENGES
9.2.4. FORUS HEALTH PVT LTD
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. PRODUCT LIST
9.2.4.3. STRENGTHS & CHALLENGES
9.2.5. HEIDELBERG ENGINEERING GMBH
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. PRODUCT LIST
9.2.5.3. STRENGTHS & CHALLENGES
9.2.6. KOWA COMPANY LTD
9.2.6.1. COMPANY OVERVIEW
9.2.6.2. PRODUCT LIST
9.2.6.3. STRENGTHS & CHALLENGES
9.2.7. NIDEK CO LTD
9.2.7.1. COMPANY OVERVIEW
9.2.7.2. PRODUCT LIST
9.2.7.3. STRENGTHS & CHALLENGES
9.2.8. OPTOS PLC
9.2.8.1. COMPANY OVERVIEW
9.2.8.2. PRODUCT LIST
9.2.8.3. STRENGTHS & CHALLENGES
9.2.9. SANTEC CORPORATION
9.2.9.1. COMPANY OVERVIEW
9.2.9.2. PRODUCT LIST
9.2.9.3. STRENGTHS & CHALLENGES
9.2.10. TOPCON CORPORATION
9.2.10.1. COMPANY OVERVIEW
9.2.10.2. PRODUCT LIST
9.2.10.3. STRENGTHS & CHALLENGES


LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - RETINAL IMAGING DEVICES
TABLE 2: MARKET BY DEVICE, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 3: MARKET BY DEVICE, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 4: MARKET BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 5: MARKET BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 6: MARKET BY FUNDUS CAMERAS, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 7: MARKET BY FUNDUS CAMERAS, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 8: MARKET BY RETINAL ULTRASOUND IMAGING SYSTEMS, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 9: MARKET BY RETINAL ULTRASOUND IMAGING SYSTEMS, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 10: MARKET BY APPLICATION, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 11: MARKET BY APPLICATION, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 12: MARKET BY INDICATION, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 13: MARKET BY INDICATION, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 14: EUROPE MARKET, COUNTRY ANALYSIS, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 15: EUROPE MARKET, COUNTRY ANALYSIS, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 16: KEY PLAYERS OPERATING IN THE EUROPEAN MARKET
TABLE 17: LIST OF MERGERS & ACQUISITIONS
TABLE 18: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 19: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 20: LIST OF BUSINESS EXPANSIONS & DIVESTITURES


LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR EUROPE
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: KEY BUYING CRITERIA
FIGURE 8: SEGMENT GROWTH POTENTIAL, BY DEVICE, IN 2025
FIGURE 9: OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 10: SEGMENT GROWTH POTENTIAL, BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, IN 2025
FIGURE 11: SPECTRAL-DOMAIN OCT (SD-OCT) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 12: SWEPT-SOURCE OCT (SS-OCT) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 13: HANDHELD OCT MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 14: FLUORESCEIN ANGIOGRAPHY DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 15: FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 16: SEGMENT GROWTH POTENTIAL, BY FUNDUS CAMERAS, IN 2025
FIGURE 17: MYDRIATIC FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 18: NON-MYDRIATIC FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 19: HYBRID FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 20: ROP FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 21: RETINAL ULTRASOUND IMAGING SYSTEMS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 22: SEGMENT GROWTH POTENTIAL, BY RETINAL ULTRASOUND IMAGING SYSTEMS, IN 2025
FIGURE 23: OPHTHALMIC A-SCAN ULTRASOUND MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 24: OPHTHALMIC B-SCAN ULTRASOUND MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 25: OPHTHALMIC ULTRASOUND BIOMICROSCOPES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 26: OPHTHALMIC PACHYMETERS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 27: ULTRA WIDEFIELD RETINAL IMAGING DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 28: WIDEFIELD RETINAL IMAGING DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 29: OTHER DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 30: SEGMENT GROWTH POTENTIAL, BY APPLICATION, IN 2025
FIGURE 31: DISEASE DIAGNOSIS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 32: TREATMENT MONITORING MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 33: RESEARCH AND DEVELOPMENT MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 34: SEGMENT GROWTH POTENTIAL, BY INDICATION, IN 2025
FIGURE 38: DIABETIC RETINOPATHY MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 35: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 36: GLAUCOMA MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 37: RETINAL VEIN OCCLUSION MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 38: OTHER INDICATIONS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 39: EUROPE RETINAL IMAGING DEVICES MARKET, COUNTRY OUTLOOK, 2025 & 2034 (IN %)
FIGURE 40: GERMANY MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 41: UNITED KINGDOM MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 42: FRANCE MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 43: ITALY MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 44: SPAIN MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 45: BELGIUM MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 46: POLAND MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 54: REST OF EUROPE MARKET SIZE, 2026-2034 (IN $ MILLION)